vision-research.eu - The Gateway to European Vision Research

RNAi gene silencing technology in form of ophthalmic drops completes Phase 1a clinical trial

July 22, 2010

In Spain, the first product based on interference RNA (RNAi) technology is an ophthalmic treatment in the form of drops to treat elevated IOP and glaucoma.

SYL040012 has just completed its first clinical trial, having been administered to 30 healthy volunteers.

<- Back to: News